Anixa Biosciences to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference


SAN JOSE, Calif., Sept. 8, 2020 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual 2020 H.C. Wainwright Global Investment Conference being held September 14-16, 2020. 

During the presentation, Dr. Kumar will provide an overview of Anixa's business and highlight recent corporate achievements, including its discovery of therapeutic candidates against Covid-19, as well as anticipated milestones in its breast cancer vaccine and CAR-T based ovarian cancer therapeutic programs.

Details of Anixa's presentation are as follows:


2020 H.C. Wainwright 22nd Annual Global Investment



Wednesday, September 16, 2020



10:00 a.m. ET


Login Information:

About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease.  Anixa's therapeutic portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function.  Anixa's vaccine portfolio consists of a technology focused on the immunization against a "retired" protein, α-Lactalbumin, to prevent triple negative breast cancer (TNBC), the most lethal form of breast cancer.  Anixa continually examines emerging technologies in complementary fields for further development and commercialization.  Additional information is available at

Forward-Looking Statements:  Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results.  We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements.  Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.  These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.  You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Anixa contact:
Mike Catelani

Tiberend Strategic Advisors, Inc.
Miriam Miller (Investors)

Johanna Bennett (Media)



Cision View original content to download multimedia:

SOURCE Anixa Biosciences, Inc.

Company Codes: NASDAQ-NMS:ANIX

Back to news